"American Medical Association Approves AI-Powered Coronary Heart Disease Tests for Reimbursement"
Cardio Diagnostics, an AI-powered precision cardiovascular medicine company, has been granted two dedicated reimbursement codes by the American Medical Association for its AI-driven coronary heart disease (CHD) tests, marking a significant step toward payer billing and payment for the company’s groundbreaking tests. These codes will facilitate broader adoption of PrecisionCHD, an integrated genetic-epigenetic clinical blood test to aid in the diagnosis of CHD, and Epi+Gen CHD for evaluating the likelihood of a patient experiencing a CHD event. The company's technology aims to combat the growing problem of heart disease, offering non-invasive, scalable, and cost-effective diagnostic solutions for CHD, with the potential to improve patient outcomes and reduce healthcare expenditure.
